REDUCE Trial PFO Selection Criteria Model (Eligibility RoPE PASCAL)

Clinical calculation support · Verify results before clinical use

Patient assessment

Complete trial eligibility fields first. RoPE and PASCAL assessment fields are optional.

REDUCE · RoPE · PASCAL

1. Core trial criteria

These fields assess selected REDUCE trial inclusion criteria and key exclusion criteria.

Documented by appropriate bubble study and/or echocardiographic assessment.

This was present in the original calculator but should not be interpreted as a verified standalone REDUCE protocol exclusion.

2. PFO anatomy

Use the original imaging report where possible. For PASCAL, a large shunt and/or atrial septal aneurysm constitutes a high-risk PFO feature.

PASCAL research definitions commonly use >20 bubbles in the left atrium on TEE for a large shunt; local imaging definitions may differ.

3. RoPE score variables

Complete all five variables to calculate RoPE. The patient age entered above also contributes to the score.

Clinical context

The REDUCE trial enrolled patients aged 18–59 years with cryptogenic ischemic stroke within 180 days and a PFO with right-to-left shunt. This calculator screens selected criteria only; it is not a complete reproduction of every protocol criterion.

How to interpret RoPE and PASCAL

  • RoPE score: combines age, hypertension, diabetes, prior stroke/TIA, smoking, and cortical infarct to estimate whether a discovered PFO may be causally related to an otherwise cryptogenic stroke.
  • PASCAL: combines RoPE ≥7 with high-risk PFO anatomy (large shunt and/or ASA). High RoPE plus a high-risk feature is “probable”; either one alone is “possible”; neither is “unlikely”.
  • Large shunt: published PASCAL analyses commonly define this as more than 20 bubbles in the left atrium on transesophageal echocardiography. Interpret anatomy according to the imaging method and validated local definitions.

References used for clinical verification

Søndergaard L, et al. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke (REDUCE).

N Engl J Med. 2017;377:1033–1042. DOI: 10.1056/NEJMoa1707404.

Kent DM, et al. Evaluating Therapies to Prevent Future Stroke in Patients with Patent Foramen Ovale-Related Strokes — The SCOPE Study.

NCBI Bookshelf, including RoPE attributable-fraction table and PASCAL classification. Official NCBI Bookshelf resource.

European Stroke Organisation guidelines on the diagnosis and management of patent foramen ovale after stroke.

European Stroke Journal. 2024. DOI: 10.1177/23969873241247978.

Clinical disclaimer: For clinician support and education only. The result does not replace comprehensive etiologic evaluation of ischemic stroke, multidisciplinary assessment, shared decision-making, or current guideline-directed care. REDUCE eligibility is not synonymous with an indication for PFO closure.